Nigel S. Key

28.2k total citations · 9 hit papers
348 papers, 19.3k citations indexed

About

Nigel S. Key is a scholar working on Hematology, Genetics and Internal Medicine. According to data from OpenAlex, Nigel S. Key has authored 348 papers receiving a total of 19.3k indexed citations (citations by other indexed papers that have themselves been cited), including 246 papers in Hematology, 128 papers in Genetics and 72 papers in Internal Medicine. Recurrent topics in Nigel S. Key's work include Blood Coagulation and Thrombosis Mechanisms (107 papers), Hemophilia Treatment and Research (95 papers) and Hemoglobinopathies and Related Disorders (74 papers). Nigel S. Key is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (107 papers), Hemophilia Treatment and Research (95 papers) and Hemoglobinopathies and Related Disorders (74 papers). Nigel S. Key collaborates with scholars based in United States, Canada and Italy. Nigel S. Key's co-authors include Nigel Mackman, Alok Srivastava, Robert P. Hebbel, Arne Slungaard, Rachel E. Tilley, Kenneth I. Ataga, Alok A. Khorana, Soheir Adam, Howard A. Liebman and Anna Falanga and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Nigel S. Key

334 papers receiving 18.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for the management of hemophilia

2012 1.4k citations Nigel S. Key et al. profile →
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014

2015 968 citations Gary H. Lyman, Kari Bohlke et al. Journal of Clinical Oncology profile →
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

2019 934 citations Nigel S. Key, Alok A. Khorana et al. Journal of Clinical Oncology profile →
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

2013 544 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis

2007 529 citations Nigel S. Key et al. profile →
Definitions in hemophilia: communication from the SSC of the ISTH

2014 528 citations Nigel S. Key et al. Journal of Thrombosis and Haemostasis profile →
D-dimer antigen: current concepts and future prospects

2008 453 citations Nigel S. Key et al. Blood profile →
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

2019 273 citations Amy D. Shapiro, Nigel S. Key et al. profile →
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update

2023 135 citations Nigel S. Key, Alok A. Khorana et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Nigel S. Key

Since Specialization

Citations

This map shows the geographic impact of Nigel S. Key's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel S. Key with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel S. Key more than expected).

Fields of papers citing papers by Nigel S. Key

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel S. Key. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel S. Key. The network helps show where Nigel S. Key may publish in the future.

Co-authorship network of co-authors of Nigel S. Key

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel S. Key. A scholar is included among the top collaborators of Nigel S. Key based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel S. Key. Nigel S. Key is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model 2025 ·Blood Advances ·(unknown), (unknown), Steven P. Grover, (unknown), (unknown), Chatphatai Moonla, Michael W. Henderson, Vimal K. Derebail, Dougald M. Monroe, Patrick Ellsworth, Rafał Pawliński, Małgorzata Kasztan, Nigel S. Key	1
2	Rapid detection of fibrinolytic activation in postpartum hemorrhage and acute obstetric coagulopathy using a novel assay 2025 ·Blood Advances ·Anton Ilich, (unknown), Chatphatai Moonla, (unknown), (unknown), (unknown), (unknown), P. Vincent Jenkins, (unknown), Sarah Bell, Rachel Collis, (unknown), Nicola J. Mutch, Nigel S. Key	0
3	Adverse clinical outcomes associated with sickle cell trait at high altitude 2024 ·Haematologica ·Katherine A. Stafford, (unknown), Rushad Patell, Nigel S. Key	1
4	Hypertonicity and/or acidosis induce marked rheological changes under hypoxic conditions in sickle trait red blood cells 2024 ·British Journal of Haematology ·Patrick Ellsworth, (unknown), (unknown), Anton Ilich, (unknown), Chatphatai Moonla, Dougald M. Monroe, Rafał Pawliński, Nigel S. Key	3
5	Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study 2023 ·Journal of Thrombosis and Haemostasis ·Floris T.M. Bosch, Elena Campello, Frits I. Mulder, Anton Ilich, Michael W. Henderson, (unknown), Sabrina Gavasso, Antonio Pea, Roberto Salvia, Hanneke Wilmink, Hans‐Martin Otten, Nick van Es, Nigel S. Key, Harry R. Büller, Paolo Simioni	4
6	Advanced practice provider–led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilization 2023 ·Research and Practice in Thrombosis and Haemostasis ·(unknown), Raj S. Kasthuri, Nigel S. Key, Micah J. Mooberry, Samuel Wilson, Stephan Moll	1
7	Plasma Kallikrein as a Forgotten Clotting Factor 2023 ·Seminars in Thrombosis and Hemostasis ·Katherine J. Kearney, Henri M.H. Spronk, Jonas Emsley, Nigel S. Key, Helen Philippou	9
8	A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment? 2023 ·Journal of Thrombosis and Haemostasis ·Leonard A. Valentino, Margareth C. Ozelo, Roland W. Herzog, Nigel S. Key, Allyson M. Pishko, Margaret V. Ragni, Benjamin J. Samelson‐Jones, David Lillicrap	11
9	Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial 2022 ·Blood ·Terry Gernsheimer, Siobhan P. Brown, Darrell J. Triulzi, Nigel S. Key, Nahed El Kassar, Heather Herren, (unknown), Michael Boyiadzis, Brandi Reeves, (unknown), Monica B. Pagano, Scott S. Emerson, Susanne May	25
10	Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure 2021 ·Blood ·Michael W. Henderson, Erica Sparkenbaugh, Shaobin Wang, Anton Ilich, Denis F. Noubouossie, Reiner K. Mailer, Thomas Renné, Matthew J. Flick, James P. Luyendyk, Zu‐Lin Chen, Sidney Strickland, R. Todd Stravitz, Keith R. McCrae, Nigel S. Key, Rafał Pawliński	20
11	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways 2020 ·Blood ·Denis F. Noubouossie, Michael W. Henderson, Micah J. Mooberry, Anton Ilich, Patrick Ellsworth, Mark Piegore, Sarah Skinner, Rafał Pawliński, Ian J. Welsby, Thomas Renné, Maureane Hoffman, Dougald M. Monroe, Nigel S. Key	66
12	High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease 2020 ·Journal of Thrombosis and Haemostasis ·Erica Sparkenbaugh, Małgorzata Kasztan, Michael W. Henderson, Patrick Ellsworth, (unknown), (unknown), Brandi Reeves, Nigel S. Key, Sidney Strickland, Keith R. McCrae, (unknown), Rafał Pawliński	9
13	An exploratory study of the effects of strenuous exercise on markers of coagulation activation, circulating microparticles, and inflammation in sickle cell trait 2020 ·SHILAP Revista de lepidopterología ·Sarah Skinner, Eric D. Ryan, (unknown), Robert G. McMurray, Nigel S. Key, Micah J. Mooberry	1
14	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update breakdown → 2019 ·Journal of Clinical Oncology ·Nigel S. Key, Alok A. Khorana, Nicole M. Kuderer, Kari Bohlke, Agnes Lee, Juan I. Arcelus, Sandra L. Wong, Edward P. Balaban, Christopher R. Flowers, Charles W. Francis, (unknown), Ajay K. Kakkar, Mark N. Levine, Howard A. Liebman, Margaret A. Tempero, Gary H. Lyman, Anna Falanga	934
15	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease 2019 ·Blood ·Camille Faës, Anton Ilich, (unknown), Erica Sparkenbaugh, Michael W. Henderson, (unknown), Joan D. Beckman, Patrick Ellsworth, Denis F. Noubouossie, (unknown), Mark Piegore, Céline Renoux, Wolfgang Bergmeier, Yara Park, Kenneth I. Ataga, Brian C. Cooley, Alisa S. Wolberg, Nigel S. Key, Rafał Pawliński	52
16	Hemoglobin Levels, Sex, Race and Coronary Heart Disease Risk in the Reasons for Geographic and Racial Differences in Stroke Study 2017 ·Blood ·Damon E. Houghton, Alicia M. Ellis, Mary Cushman, (unknown), Nigel S. Key, Monika M. Safford, George Howard, Neil A. Zakai	1
17	Synthetic oligosaccharides can replace animal-sourced low–molecular weight heparins 2017 ·Science Translational Medicine ·Yongmei Xu, Kasemsiri Chandarajoti, Xing Zhang, Vijayakanth Pagadala, Wenfang Dou, Debra Hoppensteadt, Erica Sparkenbaugh, Brian C. Cooley, (unknown), Nigel S. Key, (unknown), Jawed Fareed, Robert J. Linhardt, Rafał Pawliński, Jian Liu	87
18	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014 breakdown → 2015 ·Journal of Clinical Oncology ·Gary H. Lyman, Kari Bohlke, Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan I. Arcelus, Edward P. Balaban, Jeffrey Clarke, Christopher R. Flowers, Charles W. Francis, (unknown), Ajay K. Kakkar, Nigel S. Key, Mark N. Levine, Howard A. Liebman, Margaret A. Tempero, Sandra L. Wong, Mark R. Somerfield, Anna Falanga	968
19	Sickle cell trait and the risk of venous thromboembolism among blacks 2007 ·Blood ·Harland Austin, Nigel S. Key, Jane M. Benson, Cathy Lally, Nicole F. Dowling, Carolyn Whitsett, W. Craig Hooper	192
20	Factor IX Inhibitors and Anaphylaxis in Hemophilia B 1997 ·The American journal of pediatric hematology/oncology ·Indira Warrier, Bruce M. Ewenstein, Marion A. Koerper, Amy D. Shapiro, Nigel S. Key, Donna DiMichele, Robert Miller, John Pasi, Georges E. Rivard, Steve S. Sommer, Jacob Katz, Frauke Bergmann, Rolf Ljung, Pia Petrini, Jeanne M. Lusher	128

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact